ASH 2021 – Focused on MDS

The 2021 American Society of Hematology Annual Meeting (ASH) annual meeting, the premier event in malignant and non-malignant hematology, will take place December 11-14, virtually and in-person in Atlanta, Georgia. This year’s scientific program includes preclinical and late-stage research into the diagnosis, treatment, and prevention of myelodysplastic syndromes (MDS).

High Complete Response Rates With Magrolimab and Azacitidine Plus Venetoclax in Newly Diagnosed, High-Risk...

According to results from a phase I/II study, more than 90% of older and high-risk patients with newly diagnosed...

Polycythemia Vera Patients Have Improved Hematocrit Response With Rusfertide

Treatment with the investigational injectable hepcidin mimetic rusfertide effectively controlled levels of hematocrit and significantly reduced the need for...
Cancer Cell

Preclinical Model Shows Promise of Magrolimab Plus Venetoclax-Azacitidine in AML

In in vitro and in vivo preclinical models, the combination of magrolimab with venetoclax plus azacitidine increased phagocytosis and...

Curated Journal Abstracts

Advertisement
Advertisement